Can we improve the prognosis of HER2+ Breast cancers in Low income countries: The Moroccan experience

Abstract

Background: Breast cancer is a frequent heterogeneous disease among women, studies using gene microarray technology changed the way invasive breast cancers are categorized, it can now be classified at least in 4 classes: Luminal A, Luminal B, Basal like, HER2+; the immunohistochemical analyses of expression of estrogen receptor(ER), progesterone receptor(PR), and human epidermal growth factor receptor 2(HER2), are widely used to divide into these 4 breast cancer subtypes. The aim of this study is to demonstrate the impact of an optimal care on the prognosis of tumors that were previously worst prognosis ones in LMIC.